🏢 From Evergrande’s Fall to India’s Pharma Rise
Evergrande’s collapse shows the danger of debt-fuelled growth, while India’s CDMO sector highlights how sustainable demand can drive resilience.
Once upon a time, Evergrande was China’s pride — the world’s largest real estate developer, employing millions and symbolising urbanisation. Its founder rose from poverty to become China’s richest man. At its peak, Evergrande had projects in 280 cities and pre-sold over a million homes.
But beneath the glitter was a fragile truth. Evergrande ran on a perpetual motion machine of debt — borrowing heavily, selling apartments before they were built, and using that cash to fuel even more projects. When China imposed its “Three Red Lines” policy (debt limits) in 2020, the engine stalled. Evergrande defaulted, protests erupted, and $340 billion of liabilities crushed families, banks, and local governments.
It’s a cautionary tale: growth without sustainability eventually collapses.
Now, contrast that with India’s pharmaceutical CDMO industry. Unlike real estate bubbles, pharma demand is structural: people need medicines regardless of economic cycles. Global trends — obesity drugs like Ozempic, supply-chain diversification away from China, and rising R&D outsourcing — are creating tailwinds for Indian CDMOs.
Think of CDMOs as the “invisible factories” behind the world’s biggest drugs. They don’t sell brands, but they enable innovation by handling manufacturing and development for global pharma giants.
For India, this is a golden moment.
CDMOs (Syngene